PDUFA VI “Breakthrough” Fee Unlikely; FDA Wants Fewer Obligations, Not New Metrics
This article was originally published in RPM Report
FDA Office of New Drugs Director John Jenkins is making a case against adding “Breakthrough” user fees to PDUFA VI to better fund the program and cut back on the number of unqualified requests for designation. Rather than seek additional funding for specific programs, FDA wants fewer obligations under the user fee program; the agency is pushing back against industry proposals to add more formal meetings.
You may also be interested in...
FDA tells industry that proposal on trials also can’t use SPA-like process.
Drug sponsors are eager to use FDA’s new “breakthrough” therapy development pathway, and the agency is granting designations at a much faster rate than originally expected. But the “all hands on deck” approach required by FDA officials for breakthrough is resource-intensive at a time when the budget sequestration is preventing the agency from accessing all its available user fee funding. Is the popular program at risk?
In a podcast interview, Janet Woodcock talks about review deadlines, prioritizing pre-approval inspections, and how advisory committees could be held in an era of social distancing.